An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)

Trial Profile

An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs AAV-REP1 (Primary)
  • Indications Choroideremia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 According to a NightstaRx media release, data from this study were published in The New England Journal of Medicine in 2016.
    • 16 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.
    • 16 Mar 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Feb 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top